Shopping Cart
Remove All
Your shopping cart is currently empty
YLF-466D (C24) is a novel AMPK activator that inhibits platelet aggregation.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $31 | In Stock | In Stock | |
| 5 mg | $76 | In Stock | In Stock | |
| 10 mg | $119 | In Stock | In Stock | |
| 25 mg | $209 | In Stock | In Stock | |
| 50 mg | $298 | In Stock | In Stock | |
| 100 mg | $413 | In Stock | In Stock | |
| 200 mg | $568 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $79 | In Stock | In Stock |
| Description | YLF-466D (C24) is a novel AMPK activator that inhibits platelet aggregation. |
| In vitro | The study investigates the impact of YLF-466D on platelet AMPK activation and its potential to inhibit platelet aggregation. Activation of platelet AMPK by YLF-466D is confirmed through phosphorylation at Thr172, leading to the suppression of platelet aggregation triggered by thrombin, ADP, and collagen. This demonstrates that YLF-466D's anti-aggregatory effect is broad and not specific to the type of platelet agonist. The effects of YLF-466D on AMPK activation and aggregation inhibition are concentration-dependent, showing maximal effectiveness at 150 μM. The IC50 values for inhibiting aggregation induced by thrombin, ADP, and collagen are approximately 84, 55, and 87 μM, respectively. |
| Synonyms | C24 |
| Molecular Weight | 465.93 |
| Formula | C29H20ClNO3 |
| Cas No. | 1273323-67-3 |
| Smiles | OC(=O)c1cccc(CN2C(=O)\C(=C(/c3ccccc3)c3ccc(Cl)cc3)c3ccccc23)c1 |
| Relative Density. | 1.358 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (193.16 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.08 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.